The TNF receptor superfamily in co-stimulating and co-inhibitory responses

LK Ward-Kavanagh, WW Lin, JR Šedý, CF Ware - Immunity, 2016 - cell.com
Cytokines related to tumor necrosis factor (TNF) provide a communication network essential
for coordinating multiple cell types into an effective host defense system against pathogens …

High endothelial venules (HEVs) in immunity, inflammation and cancer

L Blanchard, JP Girard - Angiogenesis, 2021 - Springer
High endothelial venules (HEVs) are specialized blood vessels mediating lymphocyte
trafficking to lymph nodes (LNs) and other secondary lymphoid organs. By supporting high …

Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases

M Croft, RM Siegel - Nature Reviews Rheumatology, 2017 - nature.com
TNF blockers are highly efficacious at dampening inflammation and reducing symptoms in
rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing …

Realigning the LIGHT signaling network to control dysregulated inflammation

CF Ware, M Croft, GA Neil - Journal of Experimental Medicine, 2022 - rupress.org
Advances in understanding the physiologic functions of the tumor necrosis factor
superfamily (TNFSF) of ligands, receptors, and signaling networks are providing deeper …

Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …

J Rodríguez-Carrio, A Burska, PG Conaghan… - RMD open, 2023 - rmdopen.bmj.com
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …

Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus

AC Labonte, B Kegerreis, NS Geraci, P Bachali… - PLoS …, 2018 - journals.plos.org
Systemic lupus erythematosus (SLE) is characterized by abnormalities in B cell and T cell
function, but the role of disturbances in the activation status of macrophages (Mϕ) has not …

Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double …

EW St. Clair, AN Baer, C Wei, G Noaiseh… - Arthritis & …, 2018 - Wiley Online Library
Objective To evaluate the clinical efficacy and safety of baminercept, a lymphotoxin β
receptor IgG fusion protein (LT βR‐Ig), for the treatment of primary Sjögren's syndrome (SS) …

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE

WP Kennedy, R Maciuca, K Wolslegel… - Lupus science & …, 2015 - lupus.bmj.com
Objectives The interferon (IFN) signature (IS) in patients with systemic lupus erythematosus
(SLE) includes over 100 genes induced by type I IFN pathway activation. We developed a …

Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

A Burska, J Rodríguez-Carrio, R Biesen, WA Dik… - RMD open, 2023 - rmdopen.bmj.com
Objectives To systematically review the literature for assay methods that aim to evaluate type
I interferon (IFN-I) pathway activation and to harmonise-related terminology. Methods Three …

Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy

H Tang, M Zhu, J Qiao, YX Fu - Cellular & molecular immunology, 2017 - nature.com
Tertiary lymphoid structures (TLS) often develop at sites of persistent inflammation, including
cancers and autoimmune diseases. In most cases, the presence of TLS correlates with …